These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Carpenter SL; Mathew P Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165 [TBL] [Abstract][Full Text] [Related]
24. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma. Sørensen JV Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044 [TBL] [Abstract][Full Text] [Related]
25. [Influence of antiplasmin on fibrinolysis and fibrinogenolysis]. Bratus' GM; Byshevskiĭ ASh Ukr Biokhim Zh; 1971; 43(2):178-82. PubMed ID: 4254692 [No Abstract] [Full Text] [Related]
26. Trinitrophenyl-derivative of urinary trypsin inhibitor: a strong antifibrinolytic agent. Sumi H; Hamada H; Maehara S; Yoshida E; Tsushima H; Maruyama M; Mihara H Acta Haematol; 1987; 78(4):225-8. PubMed ID: 2962413 [TBL] [Abstract][Full Text] [Related]
27. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491 [TBL] [Abstract][Full Text] [Related]
28. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Collen D; Lijnen HR Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451 [TBL] [Abstract][Full Text] [Related]
29. A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin. Mettinger KL; Egberg N Thromb Res; 1982 May; 26(3):203-10. PubMed ID: 6810498 [TBL] [Abstract][Full Text] [Related]
31. Fibrinolytic activity and protein C in preeclampsia. Aznar J; Gilabert J; Estellés A; España F Thromb Haemost; 1986 Jun; 55(3):314-7. PubMed ID: 3092388 [TBL] [Abstract][Full Text] [Related]
32. Molecular mechanism of fibrinolysis. Lijnen HR; Collen D Adv Exp Med Biol; 1984; 164():217-28. PubMed ID: 6421102 [No Abstract] [Full Text] [Related]
33. [Role of the initial level of plasminogen activator in changes in fibrinolysis]. Andreenko GV; Liutova LV; Karabasova MA; Podorol'skaia LV; Serebriakova TN Fiziol Zh SSSR Im I M Sechenova; 1983 Mar; 69(3):380-5. PubMed ID: 6343132 [TBL] [Abstract][Full Text] [Related]
36. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. Glas-Greenwalt P; Kant KS; Allen C; Pollak VE J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000 [TBL] [Abstract][Full Text] [Related]
37. Observations on fibrinolysis; plasminogen, plasmin, and antiplasmin content of human blood. MACFARLANE RG; PILLING J Lancet; 1946 Oct; 2(6425):562-5. PubMed ID: 21001709 [No Abstract] [Full Text] [Related]
39. Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma. Hender U; Collen D Thromb Res; 1976 Jun; 8(6):875-9. PubMed ID: 134465 [No Abstract] [Full Text] [Related]